These results suggested that other pathways or molecules regulating actomyosin (e.g., myosin light-chain kinase or zipper interacting protein kinase75) or cell-ECM adhesion (e.g., talin76) may play a critical role in the activation of ATF5 in cancer cells on stiff ECMs. This evidence concerns the gene MYLK and cancer.